131 related articles for article (PubMed ID: 9468023)
41. Specific localization, gamma camera imaging, and intracellular trafficking of radiolabelled chimeric anti-G(D3) ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts.
Lee FT; Rigopoulos A; Hall C; Clarke K; Cody SH; Smyth FE; Liu Z; Brechbiel MW; Hanai N; Nice EC; Catimel B; Burgess AW; Welt S; Ritter G; Old LJ; Scott AM
Cancer Res; 2001 Jun; 61(11):4474-82. PubMed ID: 11389078
[TBL] [Abstract][Full Text] [Related]
42. Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients.
Cremonesi M; Ferrari M; Chinol M; Stabin MG; Grana C; Prisco G; Robertson C; Tosi G; Paganelli G
Eur J Nucl Med; 1999 Feb; 26(2):110-20. PubMed ID: 9933344
[TBL] [Abstract][Full Text] [Related]
43. Pre-targeted radioimmunotherapy of human colon cancer xenografts in athymic mice using streptavidin-CC49 monoclonal antibody and 90Y-DOTA-biotin.
Domingo RJ; Reilly RM
Nucl Med Commun; 2000 Jan; 21(1):89-96. PubMed ID: 10717908
[TBL] [Abstract][Full Text] [Related]
44. Pretargeted radioimmunotherapy of cancer: progress step by step.
Boerman OC; van Schaijk FG; Oyen WJ; Corstens FH
J Nucl Med; 2003 Mar; 44(3):400-11. PubMed ID: 12621007
[TBL] [Abstract][Full Text] [Related]
45. Role of biotin-binding affinity in streptavidin-based pretargeted radioimmunotherapy of lymphoma.
Hamblett KJ; Press OW; Meyer DL; Hamlin DK; Axworthy D; Wilbur DS; Stayton PS
Bioconjug Chem; 2005; 16(1):131-8. PubMed ID: 15656584
[TBL] [Abstract][Full Text] [Related]
46. Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models.
van Schaijk FG; Oosterwijk E; Molkenboer-Kuenen JD; Soede AC; McBride BJ; Goldenberg DM; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2005 Mar; 46(3):495-501. PubMed ID: 15750164
[TBL] [Abstract][Full Text] [Related]
47. Pretargeting of bacterial endocarditis in rats with streptavidin and 111In-labeled biotin.
Fogarasi M; Pullman J; Winnard P; Hnatowich DJ; Rusckowski M
J Nucl Med; 1999 Mar; 40(3):484-90. PubMed ID: 10086715
[TBL] [Abstract][Full Text] [Related]
48. Preparation, characterization, and biological evaluation of a streptavidin-chimeric t84.66 conjugate for antibody pretargeting.
Jia F; Shelton TD; Lewis MR
Cancer Biother Radiopharm; 2007 Oct; 22(5):654-64. PubMed ID: 17979568
[TBL] [Abstract][Full Text] [Related]
49. Novel preparation and characterization of a trastuzumab-streptavidin conjugate for pre-targeted radionuclide therapy.
Hainsworth JE; Harrison P; Mather SJ
Nucl Med Commun; 2006 May; 27(5):461-71. PubMed ID: 16609358
[TBL] [Abstract][Full Text] [Related]
50. Drug targeting to the brain using avidin-biotin technology in the mouse; (blood-brain barrier, monoclonal antibody, transferrin receptor, Alzheimer's disease).
Jeong Lee H; Pardridge WM
J Drug Target; 2000; 8(6):413-24. PubMed ID: 11328667
[TBL] [Abstract][Full Text] [Related]
51. Immunotargeting of streptavidin to the pulmonary endothelium.
Muzykantov VR; Atochina EN; Gavriljuk V; Danilov SM; Fisher AB
J Nucl Med; 1994 Aug; 35(8):1358-65. PubMed ID: 8046494
[TBL] [Abstract][Full Text] [Related]
52. A universal pretargeting system for cancer detection and therapy using bispecific antibody.
Sharkey RM; McBride WJ; Karacay H; Chang K; Griffiths GL; Hansen HJ; Goldenberg DM
Cancer Res; 2003 Jan; 63(2):354-63. PubMed ID: 12543788
[TBL] [Abstract][Full Text] [Related]
53. Streptavidin in antibody pretargeting. 2. Evaluation Of methods for decreasing localization of streptavidin to kidney while retaining its tumor binding capacity.
Wilbur DS; Hamlin DK; Buhler KR; Pathare PM; Vessella RL; Stayton PS; To R
Bioconjug Chem; 1998; 9(3):322-30. PubMed ID: 9576806
[TBL] [Abstract][Full Text] [Related]
54. Tumor pretargeting in mice using (99m)Tc-labeled morpholino, a DNA analog.
Liu G; Mang'era K; Liu N; Gupta S; Rusckowski M; Hnatowich DJ
J Nucl Med; 2002 Mar; 43(3):384-91. PubMed ID: 11884499
[TBL] [Abstract][Full Text] [Related]
55. Clearance of circulating radio-antibodies using streptavidin or second antibodies in a xenograft model.
Marshall D; Pedley RB; Boden JA; Boden R; Begent RH
Br J Cancer; 1994 Mar; 69(3):502-7. PubMed ID: 8123481
[TBL] [Abstract][Full Text] [Related]
56. Organ selective delivery using a tissue-directed streptavidin--biotin system: targeting 5-fluorouridine via TNP-streptavidin.
Schechter B; Chen L; Arnon R; Wilchek M
J Drug Target; 1999; 6(5):337-48. PubMed ID: 10342382
[TBL] [Abstract][Full Text] [Related]
57. Biological evaluation of avidin-based tumor pretargeting with DOTA-Triazole-Biotin constructed via versatile Cu(I) catalyzed click chemistry.
Uppal JK; Varshney R; Hazari PP; Chuttani K; Kaushik NK; Mishra AK
J Drug Target; 2011 Jul; 19(6):418-26. PubMed ID: 20678008
[TBL] [Abstract][Full Text] [Related]
58. Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts.
Subbiah K; Hamlin DK; Pagel JM; Wilbur DS; Meyer DL; Axworthy DB; Mallett RW; Theodore LJ; Stayton PS; Press OW
J Nucl Med; 2003 Mar; 44(3):437-45. PubMed ID: 12621012
[TBL] [Abstract][Full Text] [Related]
59. Metal-Chelating Polymers (MCPs) with Zwitterionic Pendant Groups Complexed to Trastuzumab Exhibit Decreased Liver Accumulation Compared to Polyanionic MCP Immunoconjugates.
Liu P; Boyle AJ; Lu Y; Adams J; Chi Y; Reilly RM; Winnik MA
Biomacromolecules; 2015 Nov; 16(11):3613-23. PubMed ID: 26469142
[TBL] [Abstract][Full Text] [Related]
60. Design and synthesis of bis-biotin-containing reagents for applications utilizing monoclonal antibody-based pretargeting systems with streptavidin mutants.
Wilbur DS; Park SI; Chyan MK; Wan F; Hamlin DK; Shenoi J; Lin Y; Wilbur SM; Buchegger F; Pantelias A; Pagel JM; Press OW
Bioconjug Chem; 2010 Jul; 21(7):1225-38. PubMed ID: 20597486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]